Nuvelo Inc. About
Nuvelo Inc Nuvelo, Inc. is a publicly traded biopharmaceutical
company dedicated to the discovery, development and commercialization of life
improving therapeutics for the treatment of acute cardiovascular indications
and cancer. Nuvelo’s clinical pipeline includes three product candidates:
1. alfimeprase, a direct acting thrombolytic for the treatment of acute
peripheral arterial occlusion (PAO) and catheter occlusion; 2. rNAPc2,
an anticoagulant that inhibits factor VIIa/tissue factor and 3.
ARC183, a direct thrombin inhibitor that is being developed for use
in acute anticoagulant applications. In addition to its clinical
development pipeline, Nuvelo expects to leverage its proprietary research programs
and expertise in secreted proteins and antibody discovery to expand its pipeline
and create partnering and licensing opportunities. Alfimeprase -- A Novel Acting Thrombolytic
-- Alfimeprase is an enzyme produced by recombinant DNA technology. It is a thrombolytic
agent or blood clot dissolver that is intended to directly degrade fibrin when
delivered through a catheter at the site of a blood clot. rNAPc2
-- Factor VIIa / Tissue Factor Inhibitor --Recombinant nematode anticoagulant
protein c2 (rNAPc2) is a recombinant version of a naturally occurring protein
that has anticoagulant properties. The mechanism of action lies in its ability
to block the factor VIIa/tissue factor protease complex, which is responsible
for the initiation of blood clot formation ARC183 -- Direct Thrombin
Inhibitor --ARC183 is a DNA-based direct thrombin inhibitor that is currently
being developed as an anticoagulant / anti-thrombotic. ARC183 is currently under
investigation for its rapid onset of action and short half-life, potentially negating
the need for an antidote to stop its anticoagulant effect. This gives ARC183 the
potential to be further investigated for medical procedures such as coronary artery
bypass graft (CABG) surgery and percutaneous coronary intervention.
More Info on Nuvelo Inc.